Rate this item
(1 Vote)
Zoya Paunova, AstraZeneca Country President for Bulgaria Zoya Paunova, AstraZeneca Country President for Bulgaria

With more than 45 years history in Bulgaria, AstraZeneca is not a company that shies away from making an impact. The global company for innovative medicines is driving scientific leadership, to deliver life-changing medicines in a number of therapy areas. In Bulgaria, AstraZeneca has over 115 employees, and is awarded Best Employer five times. Zoya Paunova, AstraZeneca Country President for Bulgaria, shares more.

Why did AstraZeneca choose Bulgaria?

The company stepped in Bulgaria in 2000, on the solid local basis by its predecessors, Zeneca and ICI. Currently, the company is one of the fastest growing innovative pharmaceutical companies in Bulgaria and the world. In 2017, we managed to ensure top line sustainable growth and ended the year with increase of almost 9 percent growth. Bulgarian team members are young, talented, smart individuals with energy and drive for success, with high level of engagement to company`s priorities and mission.

Bulgaria is no longer secret jewel of Europe. Our country is well established good place for investment, work and life. Key asset are Bulgarian people: bright, intelligent and well educated young people, fluent in foreign languages. AstraZeneca aspiration is through the power of science and innovation to respond to the unmet medical need.

What is the mission of AstraZeneca as a company? Can you share with us a current example for an achievement?

The company's mission is to push the boundaries of science to deliver life-changing medicines.

In the recent years, globally, the AstraZeneca went through a difficult period related to the patents expiration of products in our portfolio. 2017 was a defining year for AstraZeneca, and in the course of it, as an undeniable success, we can quote the fact that we provided patients with access to five new medicines for treatment of oncology, cardiology and respiratory diseases. At the same time we received as well approval for new indications of already approved medicines.

With one of AstraZeneca`s medicines globally in 2018, will be treated 18 million patients with asthma and COPD. In Bulgaria we recognise as a significant success also the fact that five of our product were recognized as Product of the Year for prescription medicines.

Another focus in our activities is protecting natural resources and ensuring our products are safe at all stages in their life cycle. We are nurturing the green culture across the organization and strive to manage our environmental impacts across the entire value chain from research, development and production through patient use and final disposal.

Looking ahead, AstraZeneca Bulgarian organization will be indispensable contributor to the European aspiration to reach out and change patients’ life and acknowledged for its corporate responsible citizenship sustainable development.

Sofia, 36 Dragan Tsankov Blvd, office 801
phone: 02 44 55 000

Read 504 times

Leave a comment

Make sure you enter all the required information, indicated by an asterisk (*). HTML code is not allowed.




Over 500 representatives of the Bulgarian NGO sector, entrepreneurs and diplomats attended the annual meeting of the America for Bulgaria Foundation with its grantees in Sofia, on 30 January. Everyday...

Vagabond Interviews



Investor Claude Tabet on how Ellipse Center transforms both the cityscape and the way we work, combining business and relaxation  

Copyright © Vagabond Media Ltd 2006-2018. All Rights Reserved

This website uses cookies to ensure you get the best experience on our website